RT Journal Article
SR Electronic
T1 Evaluation of commercially available immuno-magnetic agglutination and enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.15.20172080
DO 10.1101/2020.08.15.20172080
A1 Maria Engel Moeller
A1 Jeppe Fock
A1 Pearlyn Pah
A1 Antia De La Campa Veras
A1 Melanie Bade
A1 Marco Donolato
A1 Simone Bastrup Israelsen
A1 Jesper Eugen-Olsen
A1 Thomas Benfield
A1 Frederik Neess Engsig
YR 2020
UL http://medrxiv.org/content/early/2020/08/17/2020.08.15.20172080.abstract
AB Introduction Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory coronavirus-2 (SARS-CoV-2). Fast, accurate and simple blood-based assays for quantification of anti-SARS-CoV-2 antibodies are urgently needed to identify infected individuals and keep track of the spread of disease.Methods The study included 35 plasma samples from 22 individuals with confirmed COVID-19 by real time reverse-transcriptase-polymerase-chain-reaction and 40 non-COVID-19 plasma samples. Anti-SARS-CoV-2 IgM/lgA or IgG antibodies were detected by a microfluidic quantitative immunomagnetic assay (IMA) (ViroTrack Sero COVID IgM+lgA /IgG Ab, Blusense Diagnostics, Denmark) and by enzyme-linked immunosorbent assay ((ELISA) (Eurolmmun Medizinische Labordiagnostika, Germany).Results Of the 35 plasma samples from the COVID-19 patients, 29 (82.9%) were positive for IgA/IgM or IgG by IMA and 29 samples (82.9%) were positive by ELISA. Sensitivity for only one sample per patient was 68% for IgA+IgM and 73% IgG by IMA and 73% by ELISA. For samples collected 14 days after symptom onset, the sensitivity of both IMA and ELISA was around 90%. Specificity of the IMA reached 100% compared to 95% for ELISA IgA and 97.5% for ELISA IgG.Conclusion IMA for COVID-19 is a rapid simple-to-use point of care test with sensitivity and specificity similar to a commercial ELISA.Competing Interest StatementP. Pah, A. De La C. Veras, M. Bade, J. Fock, S. and M. Donolato are employed at Blusense Diagnostics APS and have been part of the developing of ViroTrack Sero COVID IgM+IgA / IgG.Funding StatementThis work was supported by BluSense Diagnostics in forms of providing the test kits for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A waiver of individual informed consent was granted by the Regional Ethics Committee of the Capital Region of Denmark (record no. H-20040649). The study was further approved by the Danish Patient Safety Authority (record no. 31-1521-309) and the Regional Data Protection Center (record no. P-2020-260).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available and embedded in the paper. Raw data available upon request.